Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.71 USD | -0.78% | +1.52% | -12.86% |
05-10 | Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint | MT |
05-10 | Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.86% | 90.63B | |
+31.81% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.34% | 239B | |
+9.96% | 210B | |
-7.03% | 200B | |
+8.12% | 167B | |
-1.42% | 161B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $69 From $81, Maintains Buy Rating